Patents by Inventor Meehyein Kim

Meehyein Kim has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11655268
    Abstract: The present disclosure relates to a novel nucleoside or nucleotide derivative, a racemate thereof, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof; and a pharmaceutical composition for preventing or treating viral infection-associated diseases, containing the same as an active ingredient.
    Type: Grant
    Filed: January 24, 2019
    Date of Patent: May 23, 2023
    Assignee: ST PHARM CO., LTD.
    Inventors: Kyungjin Kim, Meehyein Kim, Uk-Il Kim, Yun Young Go, Hwajung Nam, Hyung Tae Bang, Jin Soo Shin, Jihye Yoon, Yejin Jang
  • Publication number: 20210040135
    Abstract: The present disclosure relates to a novel nucleoside or nucleotide derivative, a racemate thereof, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof; and a pharmaceutical composition for preventing or treating viral infection-associated diseases, containing the same as an active ingredient.
    Type: Application
    Filed: January 24, 2019
    Publication date: February 11, 2021
    Inventors: Kyungjin KIM, Meehyein KIM, UK-II KIM, Yun Young GO, Hwajung NAM, Hyung BANG, Jin Soo SHIN, Jihye YOON, Yejin JANG
  • Patent number: 8318199
    Abstract: Disclosed herein is a composite of a nanoscale particle size. The composite is able to specifically deliver therapeutic agents such as therapeutic nucleic acids or drugs to the liver and selectively release them into hepatic cells to manifest potent therapeutic effects of the therapeutic agents. The composite may be comprised of an apolipoprotein A-1 and a liposome-forming material. A composition containing the composite and a pharmaceutically acceptable carrier is disclosed.
    Type: Grant
    Filed: June 1, 2010
    Date of Patent: November 27, 2012
    Assignee: Mogam Biotechnology Research Institute
    Inventors: Meehyein Kim, Soo In Kim, Duckhyang Shin, Mahnhoon Park
  • Publication number: 20110008885
    Abstract: A linear double-stranded RNA molecule, which comprises two or more consecutively or convergently linked short interfering RNAs (siRNAs) each reducing the expression of one of different target genes, and a recombinant expression vector comprising double-stranded DNA sequence expressing the linear double-stranded RNA molecule are provided. The linear double-stranded RNA molecule or the recombinant expression vector is useful for a method of reducing expression of target genes in a cell, the method comprising introducing the linear double-stranded RNA molecule or the recombinant expression vector into the cell, whereby the encoded siRNAs target different genes and reduce expression of the target genes. It was also proved that effective gene silencing activity can be induced when each siRNA unit within the linear double-stranded RNA molecule has 18 to 24 nucleotides and, additionally, the gene silencing activity is not affected by inverted orientation of an siRNA.
    Type: Application
    Filed: July 7, 2008
    Publication date: January 13, 2011
    Applicant: Mogam Biotechnology Research Institute
    Inventors: Meehyein Kim, Duckhyang Shin, Hyeon Lee, Soo In Kim, Yeup Yoon
  • Publication number: 20100239657
    Abstract: The inventive composite having a nanoscale particle size can specifically deliver therapeutic nucleic acids or drugs to the liver and selectively release them into hepatic cells to manifest potent therapeutic effects without inducing any enzymatic abnormalities or pathological damage to the normal liver function, when administered together with the therapeutic agents.
    Type: Application
    Filed: June 1, 2010
    Publication date: September 23, 2010
    Applicant: MOGAM BIOTECHNOLOGY RESEARCH INSTITUTE
    Inventors: Meehyein KIM, Soo In Kim, Duckhyang Shin, Mahnhoon Park
  • Publication number: 20100209491
    Abstract: A method for enhancing the serum stability and lowering the immunostimulatory property of a small interfering ribonucleic acid (siRNA) which mediates RNA interference (RNAi) against a viral gene expression of hepatitis B virus (HBV) or hepatitis C virus (HCV) is provided.
    Type: Application
    Filed: May 8, 2008
    Publication date: August 19, 2010
    Applicant: MOGAM BIOTECHNOLOGY RESEARCH INSTITUTE
    Inventors: Soo In Kim, Duckhyang Shin, Hyeon Lee, Meehyein Kim, Doo-Hong Park, Yeup Yoon
  • Publication number: 20100063132
    Abstract: The present invention relates to RNA interference mediated inhibition of Hepatitis B virus (HBV) by short interfering RNA (siRNA) molecules. Specially, siRNAs of the present invention which are double-stranded RNAs concern directing the sequence-specific degradation of viral RNA in mammalian cells. Disclosed is a DNA vector encoding the RNA molecules and synthesized siRNA molecules as well as method of therapeutic treatment for inhibition of HBV gene expression and viral replication by the administration of RNA molecules of the present invention.
    Type: Application
    Filed: August 20, 2009
    Publication date: March 11, 2010
    Applicant: MOGAM BIOTECHNOLOGY RESEARCH INSTITUTE
    Inventors: Meehyein KIM, Duckhyang Shin, Soo In Kim, Mahnhoon Park
  • Publication number: 20090318531
    Abstract: The present invention relates to a therapeutic reagent for hepatitis C comprising HCV specific short interfering RNA (siRNA) as an effective ingredient. The siRNA of the invention is a double-stranded RNA specific for the nucleotide sequence of HCV which induces viral RNA degradation in mammalian cells and thereby inhibits HCV protein expression and replication. The method of the invention, which includes the step of administrating the synthetic siRNA or a DNA vector encoding the RNA, is thus effective for the treatment of HCV carrier by inhibiting HCV gene expression and replication.
    Type: Application
    Filed: May 30, 2006
    Publication date: December 24, 2009
    Applicant: Mogam Biotechnology Research Institute
    Inventors: Meehyein Kim, Duckhyang Shin, Mahnhoon Park, Soo In Kim
  • Publication number: 20080138394
    Abstract: The inventive composite having a nanoscale particle size can specifically deliver therapeutic nucleic acids or drugs to the liver and selectively release them into hepatic cells to manifest potent therapeutic effects without inducing any enzymatic abnormalities or pathological damage to the normal liver function, when administered together with the therapeutic agents.
    Type: Application
    Filed: April 27, 2007
    Publication date: June 12, 2008
    Applicant: MOGAM BIOTECHNOLOGY RESEARCH INSTITUTE
    Inventors: Meehyein KIM, Soo In Kim, Duckhyang Shin, Mahnhoon Park
  • Publication number: 20080096839
    Abstract: The present invention relates to RNA interference mediated inhibition of Hepatitis B virus (HBV) by short interfering RNA (siRNA) molecules. Specially, siRNAs of the present invention which are double-stranded RNAs concern directing the sequence-specific degradation of viral RNA in mammalian cells. Disclosed is a DNA vector encoding the RNA molecules and synthesized siRNA molecules as well as method of therapeutic treatment for inhibition of HBV gene expression and viral replication by the administration of RNA molecules of the present invention.
    Type: Application
    Filed: March 9, 2006
    Publication date: April 24, 2008
    Applicant: Mogam Biotechnology Research Institute
    Inventors: Meehyein Kim, Duckhyang Shin, Soo Kim, Mahnhoon Park